In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial-Reference-Cited by-同舟云学术

In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Published:2016-05-24 Issue: Volume:8 Page:
ISSN:1663-4365
Container-title:Frontiers in Aging Neuroscience
language:
Short-container-title:Front. Aging Neurosci.

Author:

Gejl Michael,Gjedde Albert,Egefjord Lærke,Møller Arne,Hansen Søren B.,Vang Kim,Rodell Anders,Brændgaard Hans,Gottrup Hanne,Schacht Anna,Møller Niels,Brock Birgitte,Rungby Jørgen

Publisher

Frontiers Media SA

Subject

Cognitive Neuroscience,Aging

Reference48 articles.

1. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.;Ahren;Regul. Pept.,2007

2. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in alzheimer’s disease treatment studies.;Alexander;Am. J. Psychiatry,2002

3. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers.;Bomfim;J. Clin. Invest.,2012

4. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.;Craft;Arch. Neurol.,2012

5. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria.;Dubois;Lancet Neurol.,2014

Cited by 313 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging paradigms in Alzheimer's therapy;European Journal of Pharmacology;2024-10

2. IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target;Pharmacological Research;2024-09

3. Sodium–Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia;Annals of Internal Medicine;2024-08-27

4. Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration;Biomolecules;2024-07-19

5. GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice;Neuropharmacology;2024-07